Document Detail


Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies.
MedLine Citation:
PMID:  19544775     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The estimation of organ residence time is essential for high-dose myeloablative regimens in radioimmunotherapy (RIT). Frequently, this estimation is based on a series of simple planar scans and planar processing. The authors previously performed a simulation study which demonstrated that the accuracy of this methodology is limited compared to a hybrid planar/SPECT residence time estimation method. In this work the authors applied this hybrid method to data from a clinical trial of high-dose myeloablative yttrium-90 ibritumomab tiuxetan therapy. Image data acquired from 18 patients were comprised of planar scans at five time points ranging from 1 to 144 h postinjection and abdominal and thoracic SPECT/CT scans obtained at 24 h postinjection. The simple planar processing method used in this work was based on the geometric mean method with energy window based scatter compensation. No explicit background subtraction nor object or source thickness corrections were performed. The SPECT projections were reconstructed using iterative reconstruction with compensations for attenuation, scatter, and full collimator-detector response. Large differences were observed when residence times were estimated using the simple planar method compared to the hybrid method. The differences were not constant but varied in magnitude and sign. For the dose-limiting organ (liver), the average difference was -18% and variation in the difference was 19%, similar to the differences observed in a previously reported simulation study. The authors also looked at the relationship between the weight of the patient and the liver residence time and found that there was no meaningful correlation for either method. This indicates that weight would not be an adequate proxy for an experimental estimate of residence time when choosing the activity to administer for therapy. The authors conclude that methods such as the simple planar method used here are inadequate for RIT treatment planning. More sophisticated methods, such as the hybrid SPECT/planar method investigated here, are likely to be better predictors of organ dose and, as a result, organ toxicities.
Authors:
Bin He; Richard L Wahl; George Sgouros; Yong Du; Heather Jacene; Wayne R Kasecamp; Ian Flinn; Richard J Hammes; Jay Bianco; Brad Kahl; Eric C Frey
Related Documents :
8873045 - Egs4 dosimetry calculations for cylindrically symmetric brachytherapy sources.
22541965 - Dosimetric analysis of radiation-induced gastric bleeding.
24018695 - The relationship of aphasia type and gesture production in people with aphasia.
2594965 - Probabilistic approach to obtain hit-size effectiveness functions which relate microdos...
24001185 - Intb - a data integration platform for molecular and clinical epidemiological analysis ...
6498275 - Analysis of lumped and distributed elements models of cut muscle fibers in vaseline or ...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Medical physics     Volume:  36     ISSN:  0094-2405     ISO Abbreviation:  Med Phys     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-06-23     Completed Date:  2009-07-15     Revised Date:  2014-09-12    
Medline Journal Info:
Nlm Unique ID:  0425746     Medline TA:  Med Phys     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1595-601     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antibodies, Monoclonal / therapeutic use*
Female
Humans
Lymphoma / radiotherapy*
Male
Middle Aged
Radioimmunotherapy / methods*
Radiometry / methods*
Radiopharmaceuticals / therapeutic use
Radiotherapy Dosage
Radiotherapy Planning, Computer-Assisted / methods*
Treatment Outcome
Grant Support
ID/Acronym/Agency:
R01 CA109234/CA/NCI NIH HHS; R01 CA109234-04/CA/NCI NIH HHS; R01 CA116477/CA/NCI NIH HHS; R01 CA116477-04/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Radiopharmaceuticals; 0/ibritumomab tiuxetan
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Solid water as phantom material for dosimetry of electron backscatter using low-energy electron beam...
Next Document:  Quantitative imaging of element composition and mass fraction using dual-energy CT: three-material d...